Author/Authors :
Bemanian, Mohammad Hassan Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Movahedi, Masoud Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Farhoudi, Abolhassan Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Gharagozlou, Mohammad Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Heidari Seraj, Mehran Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Pourpak, Zahra Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Nabavi, Mohammad Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Aghamohammadi, Asghar Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran , Shirkhoda, Zahra Department of Immunology - Asthma and Allergy - Children's Hospital Medical Center - Tehran University of Medical Sciences, Tehran
Abstract :
Atopic dermatitis is one of the most common allergic diseases that almost always
respond to conventional therapies with topical emollient, topical corticosteroids,
systemic antihistamines and allergic abstinence. However few cases of atopic
dermatitis with severe course do not respond to conventional therapies and high dose
of intravenous immunoglobulin or cyclosporine are recommended for them. This
clinical trial study has been done to compare the last two regimens in patients with
severe atopic dermatitis, Scoring Atopic Dermatitis (SCORAD) > 70. We included 14
patients in two groups. In group 1, eight patients were randomly selected and received
4mg/kg cyclosporine daily for 3 months and in group 2, six patients received 2g/kg
Intravenous Immunoglobulin (IVIG) as stat infusion. All patients were followed on
days 15, 30, 60 and 90 after starting the therapy. About 75% and 62.5% of patients had
positive skin tests to egg and to milk respectively. Six patients out of 14 patients did
not have skin test, so specific IgE by Radioallergosobent tests (RAST) was used for
them. All of these patients had positive RAST to egg and 66.6% against cow’s milk.
There was a significant difference in the clinical outcomes of these two groups with
a marked reduction in SCORAD of day 90th in group 1 in comparison to group 2 (Pvalue
= 0.005). No significant adverse drug reaction was seen in these two groups.
Keywords :
Atopic dermatitis , Cyclosporine , Intravenous immunoglobulin , Treatment